Parallel Advisors, LLC Cassava Sciences Inc Call Options Transaction History
Parallel Advisors, LLC
- $4.34 Billion
- Q4 2024
Call Options
1 transactions
Others Institutions Holding SAVA
# of Institutions
190Shares Held
16.4MCall Options Held
3.49MPut Options Held
8.08M-
Black Rock Inc. New York, NY3.22MShares$7.73 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.51MShares$6.03 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.01MShares$2.42 Million0.0% of portfolio
-
State Street Corp Boston, MA997KShares$2.39 Million0.0% of portfolio
-
Ubs Group Ag931KShares$2.23 Million0.0% of portfolio
About CASSAVA SCIENCES INC
- Ticker SAVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,097,900
- Market Cap $96.2M
- Description
- Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...